EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection

Jamie Guenthoer, Michelle Lilly, Tyler N Starr iD, Bernadeta Dadonaite, Klaus N Lovendahl, Jacob T Croft iD, Caitlin I Stoddard, Vrasha Chohan, Shilei Ding, Felicitas Ruiz, Mackenzie S Kopp, Andrés Finzi und 4 weitere

Proceedings of the National Academy of Sciences · 2023

DOI: 10.1073/pnas.2220948120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Jamie Guenthoer und 15 weiteren Autor:innen. Beteiligte Einrichtung: Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The antiviral benefit of antibodies can be compromised by viral escape especially for rapidly evolving viruses. Therefore, durable, effective antibodies must be both broad and potent to counter newly emerging, diverse strains. Discovery of such antibodies is critically important for SARS-CoV-2 as the global emergence of new variants of concern (VOC) has compromised the efficacy of therapeutic antibodies and vaccines. We describe a collection of broad and potent neutralizing monoclonal antibodies (mAbs) isolated from an individual who experienced a breakthrough infection with the Delta VOC. Four mAbs potently neutralize the Wuhan-Hu-1 vaccine strain, the Delta VOC, and also retain potency against the Omicron VOCs through BA.4/BA.5 in both pseudovirus-based and authentic virus assays. Three mAbs also retain potency to recently circulating VOCs XBB.1.5 and BQ.1.1 and one also potently neutralizes SARS-CoV-1. The potency of these mAbs was greater against Omicron VOCs than all but one of the mAbs that had been approved for therapeutic applications. The mAbs target distinct epitopes on the spike glycoprotein, three in the receptor-binding domain (RBD) and one in an invariant region downstream of the RBD in subdomain 1 (SD1). The escape pathways we defined at single amino acid resolution with deep mutational scanning show they target conserved, functionally constrained regions of the glycoprotein, suggesting escape could incur a fitness cost. Overall, these mAbs are unique in their breadth across VOCs, their epitope specificity, and include a highly potent mAb targeting a rare epitope outside of the RBD in SD1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Breakthrough InfectionsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingSyndactylyAntibodies, ViralHumansAntibodies, MonoclonalEpitopes

Stichwörter der Autor:innen

SARS-CoV-2monoclonal antibodiesspike glycoproteinvariants of concern

Substanzen

Antibodies, MonoclonalAntibodies, NeutralizingEpitopesSpike Glycoprotein, CoronavirusAntibodies, Viralspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
  • Department of Biochemistry, University of Utah, Salt Lake City, UT 84112.
  • Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
  • Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195.
  • Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.

ORCID-Profile: Tyler N Starr, Jacob T Croft, Jesse D Bloom, Kelly K Lee

Förderung

  • NIAID NIH HHS
  • HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • Howard Hughes Medical Institute
  • Canadian HIV Trials Network, Canadian Institutes of Health Research
  • Canada Foundation for Innovation
  • Canada Research Chairs

Zitieren

APA

Guenthoer, J., Lilly, M., Starr, T. N., Dadonaite, B., Lovendahl, K. N., Croft, J. T., Stoddard, C. I., Chohan, V., Ding, S., Ruiz, F., Kopp, M. S., Finzi, A., Bloom, J. D., Chu, H. Y., Lee, K. K., & Overbaugh, J. (2023). Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2220948120

Vancouver

Guenthoer J, Lilly M, Starr TN, Dadonaite B, Lovendahl KN, Croft JT, et al. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2220948120

BibTeX
@article{Guenthoer2023,
  author = {Guenthoer, Jamie and Lilly, Michelle and Starr, Tyler N and Dadonaite, Bernadeta and Lovendahl, Klaus N and Croft, Jacob T and Stoddard, Caitlin I and Chohan, Vrasha and Ding, Shilei and Ruiz, Felicitas and Kopp, Mackenzie S and Finzi, Andrés and Bloom, Jesse D and Chu, Helen Y and Lee, Kelly K and Overbaugh, Julie},
  title = {Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2220948120}
}
Kostenlos starten →